Stockreport

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics, Inc.  (LXEO) 
PDF LX2020 generally well tolerated across ten participants with no clinically significant complement activation  LX2020 transduction, transcription, and increased protein [Read more]